explore -WSS

explore

author：hotspot 2025-10-01 18:35:04 - browse：9

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The best solution to the drug shortages problem

focus

WSS

Drastic changes should bring profitability, startup health insurers say

J&J to emphasize cancer drugs, stop much of its vaccine research

With clinical trial data readouts, here's how to spot spin

Will the market for weight loss drugs really reach $100 billion?

What don’t we know about an Alzheimer’s drug side effect?

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

hotspot

explore

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

CDC director unscathed in first congressional testimony

In age of alternative facts, a scholarly course on calling out crap

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Wildfire smoke exposes gaps in outdoor worker protections

Diagnostic tests are hitting their mathematical limits

BioMarin wins approval for gene therapy to treat hemophilia A

Diagnostic tests are hitting their mathematical limits

The cancer drug shortage isn’t new — and neither are the solutions

Takeda, Janssen join wearable maker to measure scratching

focus

The EPA's new lead rule: How one expert crunched the numbers

Rep. Raul Ruiz on the physician shortage and more

Naloxone nonprofit donates 200,000 doses after FDA approval

Wegovy’s successful heart trial raises vital question about weight loss

Drastic changes should bring profitability, startup health insurers say

Methadone doses haven’t kept up in the age of fentanyl

focus

Wikipedia

leisure time

focus